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ABSTRACT
Introduction: The consumption of fructose has been questioned, since its increase 
has led to an associated increase in steatosis caused by nonalcoholic fatty liver 
disease. Despite the advantages presented by the zebrafish as an animal model, at 
present there are no models of steatosis by fructose in adult zebrafish. The aim of 
this study is to establish a model of hepatic steatosis by fructose in adult zebrafish.
Methods: Firstly, adult zebrafish were daily exposed to 4% or 6% fructose. Then, animals 
were exposed to 6% fructose every 2 days. The hepatic lipid accumulation was 
analyzed by Nile Red and Oil Red O staining.
Results: The daily exposure to 6% fructose showed increased accumulation of hepatic 
lipids when compared to 4% and control groups, but the same concentration showed 
no difference when the exposure happened every 2 days.
Conclusion: We can suggest the daily exposure to a concentration of 6% fructose 
can be considered as a new experimental model of adult zebrafish.
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Fructose consumption has been related to the development and progression 
of nonalcoholic fatty liver disease (NAFLD)1,2. This encompasses a broad 
spectrum of liver diseases in individuals who do not consume alcohol in 
amounts considered dangerous to the liver3,4. Injuries in NAFLD usually 
start with simple steatosis and can progress to steatohepatitis, cirrhosis, 
and eventually hepatocellular carcinoma3. In a Brazilian study, the estimated 
prevalence of hepatic steatosis was 20% in the general population5.
Fructose is found naturally in some foods, such as honey and fruits, and 
artificially in others, such as corn syrup used in soft drinks and processed 
food6. Studies in animal models with a high fructose diet have shown that it 
promotes de novo lipogenesis, formation of reactive oxygen species, increased 
intestinal microbiota, and increased risk of cardiovascular diseases7.
Animal models of NAFLD provide important information, not only elucidating 
the pathogenesis and mechanisms of disease, but also examining the effects 
of various therapeutic agents8. In this aspect, zebrafish (Danio rerio) is an 
excellent study model due to its small size, easy maintenance, low cost, high 
proliferation, and because it presents 70% homology with the mammalian 
genome9,10. Despite these advantages, and considering the relevance of 
fructose in the diet, at present there is no hepatic steatosis model for fructose 
in adult zebrafish.
In this study, we evaluated the effect of fructose at different concentrations 
and exposure times to induce hepatic steatosis.
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METHODS
Animals
Eighty adult wild-type zebrafish of both sexes 
obtained from an aquarium shop were used. 
The animals were kept in aquariums, five fish/L, 
at 28 °C ± 2 °C with light/dark cycles of 10/14 hours 
under constant aeration and were fed frozen artemia 
(BioArtémia, Brazil) in an amount of 5% of body 
weight of fish. All the aquariums of the experiment 
were maintained with fungizone, kanamycin (Gibco, 
USA), and ampicillin (Blaú, Brazil) to prevent water 
contamination.
All procedures were performed according to the 
Brazilian legislation (Law 11.794) and Resolution no. 
04/97 of the Research Ethics Committee of Hospital 
de Clínicas de Porto Alegre, which also concerns 
animal research (GPPG-HCPA protocol 13-0329).
Experimental Design
Firstly, 48 animals were divided into three 
groups (n = 16/group): groups FR4 and FR6, with 
40 g and 60 g of fructose/L of water respectively, 
and CTRL, without addition of fructose in the 
water. For exposure to fructose, the animals were 
transferred daily for 2 hours to aquariums with FR4 
or FR6 and then returned to aquariums with normal 
conditions. As a control, a group of animals received 
the same treatment as the animals of the fructose 
group. After 14 days, the animals were anesthetized 
with tricaine (400 mg/L, Sigma Aldrich, USA) and 
euthanized by exsanguination11. Livers were removed 
and frozen at -20 °C for further analysis.
After determining the adequate concentration of 
fructose to induce hepatic steatosis, the remaining 
32 animals were divided into two groups (n = 16): 
FR6 and CTRL. Exposure to fructose was performed 
every 2 days, as described above. After 20 days, 
the animals were anesthetized and euthanized by 
exsanguination11. Livers were removed and frozen 
at -20 °C for further analysis.
Analysis of Liver Lipid Deposits
For quantification of lipid deposits, pools of three 
livers were homogenized with PBS (20 mg of tissue/mL) 
(Laborclin, Brazil) and then incubated with Nile Red 
(1 mg/mL) (Sigma, USA) for 15 minutes at 37 °C. 
The fluorescence of the supernatant was measured 
in a spectrophotometer (SpectraMax M5 Molecular 
Devices, USA) at 488 nm of excitation and 550 nm 
of emission12.
To evaluate hepatic lipid deposits, the livers were 
sectioned in a cryostat, mounted on slides, and stained 
with Oil Red O (Sigma, USA). Microphotographs were 
obtained through an optical microscope (Olympus, 
Japan).
Statistical Analysis
Statistical analyzes were performed using the 
Kruskal Wallis and the Mann Whitney test and the 
statistical packages SPSS v.18 and GraphPhad Prism 
v 5.0. The significance level was set at p < 0.05.
RESULTS
When animals were daily exposed to different 
concentrations of fructose, we observed that the 
FR6 group had an increased accumulation of lipids 
(0.319±0.148) when compared to the CTRL group 
(0.112±0.283) (p = 0.042). The FR4 group (0.184±0.867) 
did not show a significant difference when compared 
to the CTRL group (Figure 1A). Oil Red O staining 
was positive in the FR6 group but negative in the 
CTRL group (Figure 1B-C). As shown in the figures, 
the hepatic tissue sample of group F6 presented 
accumulations of red-stained lipid droplets, whereas 
the control group did not.
After these results, the concentration of 6% fructose 
was chosen to be evaluated in exposures every 2 days. 
We observed there was no significant statistical 
difference between the FR6 and CTRL groups 
when the animals were exposed to fructose every 
2 days (0.059±0.177 vs. 0.030±0.0353) (Figure 2A). 
No difference was found between the groups in Oil 
Red O staining results (Figure 2B-C).
Figure 1: Evaluation of lipid content in daily exposures. 
A: Quantification of hepatic lipids by Nile Red. The FR6 
group presented an increase in lipids concentration when 
compared to the FR4 and CTRL groups. A statistical analysis 
was performed by the Kruskal Wallis test. B-C: Staining 
with Oil Red O. Unlike the CTRL group (B), the FR6 group 
presents red-colored lipid droplets (C). Magnification of 100x.
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DISCUSSION
NAFLD is currently the most common chronic liver 
disease in Western countries, since one billion people 
are estimated of currently suffering from any form of 
NAFLD13,14. Hepatic steatosis is an important concern 
in global health, because sedentary lifestyle, modern 
Western diet, and some pharmacological agents 
have been identified as critical causes of NAFLD14.
Changes in dietary habits in the last decades 
resulted in the introduction of sweeteners such as 
fructose and sucrose. The role of fructose in NAFLD 
has been questioned due to the increased presence 
of NAFLD in parallel with the rapid consumption of 
fructose15-17. Fructose is taken up into the portal 
system by hepatocytes via glucose transporter 
members 2 and 5 and is metabolized in the glycolytic 
and lipogenic pathway18,19.
There are currently several animal models of hepatic 
steatosis on exposure to fructose. Spruss et al.20 have 
shown that the addition of 30% fructose in murine 
Figure 2: Evaluation of lipid content in exposures every 
2 days. A: Quantification of hepatic lipids by Nile Red staining. 
The FR6 group presented no statistical difference when 
compared to the CTRL group. A statistical analysis was 
performed by the Mann Whitney test. B-C: Staining with 
Oil Red O. The FR6 group (B) did not present difference 
in lipid deposition compared to the CTRL group (C). 
Magnification of 100x.
drinking water for 8 weeks causes increased levels of 
triglycerides, hepatic steatosis, and increased body 
weight20. Sapp et al. used the zebrafish model, they 
analyzed larvae, and observed that a 4% concentration 
of fructose lead to hepatic steatosis21.
In this study we evaluated the effect of different 
concentrations of fructose in adult zebrafish, since this 
is an excellent study model. Our results showed that 
daily exposure to 6% fructose could increase hepatic 
lipid accumulation in adult zebrafish, but induction with 
4% fructose showed no effects on the liver. However, 
these results differ from those of Sap et al.21, which 
may be due to the fact that they studied zebrafish 
larvae and not adult fish. Thereby, we chose the 6% 
concentration for the following analyzes.
Although daily exposure to fructose is related to 
hepatic steatosis, non-daily exposure to fructose in 
adult zebrafish has not yet been evaluated. Thus, we 
tested exposure every 2 days, since we believe 
that this model best reflects the consumption of 
fructose in the diet of patients with hepatic steatosis. 
Our results showed no difference in the analysis of 
hepatic steatosis between the groups.
These previous results provide an indication that it 
is possible to use adult zebrafish as an animal model 
for the induction of hepatic steatosis by fructose. 
The use of zebrafish allows the analysis of other 
parameters such as glycemia, total cholesterol, 
triglycerides, and high-density protein (HDL), as 
well as the development of molecular studies. Since 
the objective of this study was first to determine the 
amount of fructose (4% or 6%) as well as the type 
of induction (daily or every 2 days) necessary for 
generation of hepatic steatosis, we hardly performed 
histological analyzes to use a minimum number of 
animals. Even so, future studies are necessary to 
evaluate additional parameters related to animal 
models of steatosis.
In conclusion, daily exposure to 6% fructose 
seems to represent a good experimental model of 
hepatic steatosis.
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